UTAH MEDICAL PRODUCTS INC
No SEC Form 4 filings for $UTMD in the last 30 days.
See all $UTMD insider activity →Utah Medical Products reported Q3 2026 revenue of $8.621M, down 12.1% YoY, with net income up 5.9% to $2.787M. Nine-month revenue fell 12.2% to $25.873M, and net income declined 7.4% to $8.077M. The company attributed the revenue decline to lost customers and weaker sales in key products. Management projected a full-year 2026 sales decline of about 7%.
UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact: Brian Koopman (801) 566-1200 October 22, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calend
Utah Medical Products (UTMD) offers to buy up to 650,000 shares at $75 each, a 17% premium over the 12-month average. The tender offer, approved by the board, aims to provide liquidity. UTMD's H1 2026 sales and profits declined 12% and 13% YoY, with recent EBITDA at $15.7M. CEO Cornwell believes shares are undervalued, citing industry multiples. The offer expires Oct 7 unless extended.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning UTMD (UTAH MEDICAL PRODUCTS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent UTMD coverage spans earnings, corporate actions and financial news.
Revenue decline and lower device sales suggest downward pressure on the stock.
Revenue decline and loss of two major customers suggest near‑term earnings pressure, though operating income improved modestly.
The tender offer provides a short‑term liquidity option and may support the share price near the offer price.
The premium tender may support the stock price and provide liquidity for shareholders.
A modest dividend increase signals continued shareholder returns, but it is unlikely to drive a large repricing versus broader fundamentals.
AlphAI scores every news story that mentions UTMD with an AI model for sentiment and relevance, and aggregates insider trades from UTAH MEDICAL PRODUCTS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Utah Medical Products reported Q3 2026 revenue of $8.621M, down 12.1% YoY, with net income up 5.9% to $2.787M. Nine-month revenue fell 12.2% to $25.873M, and net income declined 7.4% to $8.077M. The company attributed the revenue decline to lost customers and weaker sales in key products. Management projected a full-year 2026 sales decline of about 7%.
1 min readUTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact: Brian Koopman (801) 566-1200 October 22, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calend
2 min readUtah Medical Products (UTMD) offers to buy up to 650,000 shares at $75 each, a 17% premium over the 12-month average. The tender offer, approved by the board, aims to provide liquidity. UTMD's H1 2026 sales and profits declined 12% and 13% YoY, with recent EBITDA at $15.7M. CEO Cornwell believes shares are undervalued, citing industry multiples. The offer expires Oct 7 unless extended.
2 min readUtah Medical Products (UTMD) announced a self-tender offer to repurchase up to 650,000 shares, or 20% of its outstanding shares, at $75.00 per share. This price is 17% higher than the 12-month average and 21% higher than the 2-year average. The offer, starting September 22, is not conditioned on a minimum number of shares. The company's board approved the offer but did not recommend it to stockholders.
2 min readUtah Medical Products (Nasdaq: UTMD) said its board approved a quarterly cash dividend of $0.31 per share payable Oct. 5, 2026 to shareholders of record as of Sept. 17, 2026. The company stated this is a 1.6% increase versus the dividend declared for the same quarter a year earlier.
2 min readUTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 utmd_ex99z1.htm EXHIBIT 99.1 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 Contact: Brian Koopman (801) 566-1200 July 23, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar qua
6 min readUtah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.
3 min readUtah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.
3 min readUTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.
3 min read
